Inhibition potential of glimepiride (gli) towards important UDP-glucuronosyltransferase (UGT) isoforms in human liver

Pharmazie

Volumn 67, Issue 8, 2012, Pages 715-717

  Fu, Jian Fang ^a   Ren, Qin You ^b   Zhang, Nan Yan ^a   Gao, Bin ^a   Tu, Yan Yang ^c   Fu, Guo Qiang ^c   Li, Dao Hai ^c   Zhang, Yong Sheng ^c  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLIMEPIRIDE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B15; GLUCURONOSYLTRANSFERASE 2B7; HYMECROMONE; UNCLASSIFIED DRUG;

ARTICLE; DRUG DETOXIFICATION; DRUG ELIMINATION; DRUG INHIBITION; DRUG METABOLISM; DRUG MONITORING; HUMAN; HUMAN TISSUE; INHIBITION KINETICS; LIVER;

GLUCURONOSYLTRANSFERASE; HUMANS; HYMECROMONE; HYPOGLYCEMIC AGENTS; ISOENZYMES; KINETICS; LIVER; SUBSTRATE SPECIFICITY; SULFONYLUREA COMPOUNDS;

EID: 84866101426     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2012.1851     Document Type: Article

References (14)

1. de Morais S, Wells P (1998) Deficiency in bilirubin UDP- glucuronosyltransferase as a genetic determinant of acetaminophen toxicity. J Pharmacol Exp Ther 247: 323-331.
2. Galani V, Vyas M. (2010) In vivo and in vitro drug interactions study of glimepride with atorvastatin and rosuvastatin. J Young Pharm 2: 196-200.
3. Huang T, Fang ZZ, Yang L (2010) Strong inhibitory effect of medroxyprogesterone acetate (MPA) on UDPglucuronosyltransferase (UGT) 2B7 might induce drug-drug interactions. Pharmazie 65: 919-921.
4. Huang T, Fang ZZ, Zhang YY, Zhu LL, Feng LL, Zheng W, Cao YF, Sun DX, Yang L (2011) Inhibitory potential of chlormadinone acetate (CMA) on five important UDP-glucuronosyltransferases in human liver. Pharmazie 66: 212-215.
5. Hutt AJ, Caldwell J, Smith RL (1986) The metabolism of aspirin in man: a population study. Xenobiotica 16: 239-249.
6. Kiang TK, Ensom MH, Chang TK (2005) UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106: 97-132.
7. Knights KM, Bowalgaha K, Miners JO (2010) Spironolactone and canrenone inhibit UGT2B7-catalyzed human liver and kidney microsomal aldosterone 18beta-glucuronidation: a potential drug interaction. Drug Metab Dispos 38: 1011-1014.
8. Krishnaswamy S, Duan SX, von Moltke LL, Greenblatt DJ, Court MH (2003) Validation of serotonin (5-hydroxtryptamine) as an in vitro substrate probe for human UDP-glucuronosyltransferase (UGT) 1A6. Drug Metab Dispos 31: 133-139.
9. Lertora JJ, Rege AB, Greenspan DL, Akula S, George WJ, Hyslop NE Jr, Agrawal KC (1994) Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 56: 272-278.
10. Liu Y, Ramirez J, Ratain MJ (2011) Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors. Br J Clin Pharmacol 71: 917-920.
11. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B (1996) Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 347: 578-581.
12. Niemi M, Neuvonen PJ, Kivisto KT (2001) Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther 70: 439-445.
13. Sahai J, Gallicano K, Pakuts A, Cameron DW (1994) Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. J Infect Dis 169: 1103-1107.
14. Shobha JC, Muppidi MR (2010) Interaction between voriconazole and glimepiride. J Postgrad Med 56: 44-45.